ATE320487T1 - Ribozyme gegen eine hiv tat sequenz - Google Patents

Ribozyme gegen eine hiv tat sequenz

Info

Publication number
ATE320487T1
ATE320487T1 AT02025406T AT02025406T ATE320487T1 AT E320487 T1 ATE320487 T1 AT E320487T1 AT 02025406 T AT02025406 T AT 02025406T AT 02025406 T AT02025406 T AT 02025406T AT E320487 T1 ATE320487 T1 AT E320487T1
Authority
AT
Austria
Prior art keywords
hiv
compound
target site
ribozymes against
act sequence
Prior art date
Application number
AT02025406T
Other languages
English (en)
Inventor
Geoffrey P Symonds
Lun-Quan Sun
Original Assignee
Gene Shears Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/178,082 external-priority patent/US5712384A/en
Application filed by Gene Shears Pty Ltd filed Critical Gene Shears Pty Ltd
Application granted granted Critical
Publication of ATE320487T1 publication Critical patent/ATE320487T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02025406T 1994-01-05 1995-01-05 Ribozyme gegen eine hiv tat sequenz ATE320487T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/178,082 US5712384A (en) 1994-01-05 1994-01-05 Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US08/310,259 US6114167A (en) 1994-01-05 1994-09-21 Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence

Publications (1)

Publication Number Publication Date
ATE320487T1 true ATE320487T1 (de) 2006-04-15

Family

ID=26873946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02025406T ATE320487T1 (de) 1994-01-05 1995-01-05 Ribozyme gegen eine hiv tat sequenz

Country Status (14)

Country Link
EP (2) EP1298208B1 (de)
JP (1) JP3691849B2 (de)
CN (1) CN1267552C (de)
AT (1) ATE320487T1 (de)
AU (1) AU698730B2 (de)
CA (1) CA2180358A1 (de)
DE (1) DE69534864T2 (de)
DK (1) DK1298208T3 (de)
ES (1) ES2260376T3 (de)
IL (1) IL112261A (de)
NO (1) NO319376B1 (de)
NZ (1) NZ278432A (de)
PT (1) PT1298208E (de)
WO (1) WO1995018854A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
AU702266B2 (en) * 1995-08-25 1999-02-18 Regents Of The University Of California, The Chimeric antiviral agents which incorporate Rev binding nucleic acids
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
JP2000503527A (ja) * 1995-11-28 2000-03-28 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 条件付き複製ウイルスベクターおよびその用途
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
JP5179697B2 (ja) 2001-07-10 2013-04-10 ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド 造血前駆細胞を遺伝的に改変する方法及び改変された細胞の使用
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CN102841007A (zh) * 2012-09-05 2012-12-26 福建省农业科学院畜牧兽医研究所 一种便于鸭精子计数的精液稀释液及其使用方法
CN113549641B (zh) * 2021-06-29 2023-12-22 复旦大学 一种核酶介导的多顺反子载体及其构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
EP0578776A4 (de) * 1991-04-05 1995-04-12 Edison Animal Biotech Center Hemmung von retroviren mittels zu verpackungssequenzen komplementärer antisense-nukleinsäuren.
DE69333930T8 (de) * 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication

Also Published As

Publication number Publication date
JPH09508004A (ja) 1997-08-19
EP0753062A1 (de) 1997-01-15
NZ278432A (en) 1998-06-26
DK1298208T3 (da) 2006-07-24
NO962826D0 (no) 1996-07-04
ES2260376T3 (es) 2006-11-01
NO962826L (no) 1996-08-27
CN1145638A (zh) 1997-03-19
AU1391295A (en) 1995-08-01
EP0753062A4 (de) 1999-10-20
JP3691849B2 (ja) 2005-09-07
IL112261A (en) 2005-08-31
PT1298208E (pt) 2006-10-31
AU698730B2 (en) 1998-11-05
CN1267552C (zh) 2006-08-02
EP1298208B1 (de) 2006-03-15
IL112261A0 (en) 1995-03-30
DE69534864T2 (de) 2007-02-22
EP1298208A2 (de) 2003-04-02
DE69534864D1 (de) 2006-05-11
WO1995018854A1 (en) 1995-07-13
NO319376B1 (no) 2005-07-25
CA2180358A1 (en) 1995-07-13
EP1298208A3 (de) 2004-01-07

Similar Documents

Publication Publication Date Title
ATE320487T1 (de) Ribozyme gegen eine hiv tat sequenz
WO1999029871A3 (fr) Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map)
WO1996019568A3 (en) Stabilized ribozyme analogs
CA2340416A1 (en) Co-lyophilized complex of a nucleic acid vector and a formulating agent
CY1112430T1 (el) Λεντινοϊικο τριπλο dνα και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dνα
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
FR2741066B1 (fr) Nouveaux agents de transfection et leurs applications pharmaceutiques
DZ1759A1 (fr) Produits pharmaceutiques à base d'acide nucleique.
ATE241014T2 (de) Hiv-2 varianten
KR960703170A (ko) 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
DK0404625T3 (da) Oligonukleotidsekvenser til amplifikation af genomer af retrovirus af HIV-2 og SIV-typen samt deres anvendelser til in vitro-diagnose af infektioner forårsaget af disse virus
HUP9802926A2 (hu) Apolipoprotein A-I új variánsai
EP0329198A3 (de) Ribose- und 2-Deoxyribose-Verbindungen
DK0775745T3 (da) Cathepsin G-inhiberende aptamerer
EP0578776A4 (de) Hemmung von retroviren mittels zu verpackungssequenzen komplementärer antisense-nukleinsäuren.
FR2771753B1 (fr) Gene de chitine-desacetylase, sequence d'adn hybridable, vecteur plasmidique qui le contient et organisme transforme par ce vecteur plasmidique
DE69501081D1 (de) Oligonukleotide mit anti-cytomegalovirus wirkung
FR2701960B1 (fr) Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme.
WO1998030717A3 (en) Vegetal sequences including a polymorphic site and their uses
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
NO951444L (no) Gestagent aktive 19,11-broede 4-oestrener
SE9804298D0 (sv) New medical use
FR2734281B1 (fr) Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1298208

Country of ref document: EP

REN Ceased due to non-payment of the annual fee